66,00 <%= Resources.Global.txtUp %>
Opdateret 21-05-2018
Ændring % 0,76% Stigning i aktiekurs
Ændring 0,50 Stigning i aktiekurs
Volume 140.919
Høj 66,28
Lav 65,52
Åben 65,52
ISIN BE0003739530
Seneste luk 65,50
# af aktier 194,51M
Markedsværdi 12.837M EUR
I dag

Market closed
UCB
Markedet er lukket, åbner klokken 09:00
 
Kursudvikling Seneste 1 uge 1 måned 3 mdr 6 mdr 1 år
 
  66,00 3,5% Stigning i aktiekurs 1,1% Stigning i aktiekurs -3,6% Fald i aktiekurs 4,0% Stigning i aktiekurs 5,1% Stigning i aktiekurs
Powered by TradingView

Firmaprofil

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. maj 2018 00:24:46
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180515.2 - EUROWEB3 - 2018-05-22 00:24:46 - 2018-05-22 00:24:46 - 1 - Website: OKAY